The partnership will advance microbiome research in metabolic health, while WONDERLAB showcases SHAPE100™ research and its AKKKING™ metabolic-health formula

HONG KONG, China — WONDERLAB has signed a long-term strategic partnership with United Family Healthcare (UFH) to advance the clinical translation of microbiome research. Announced at Global Health Summit 2026, the collaboration will focus on metabolic health, weight management and age-related gut health, connecting research questions from clinical practice with evidence generation and product development.

The second Global Health Summit was held Aug. 7–8 in Hong Kong, China, at the Hong Kong Convention and Exhibition Centre. Jointly organized by New Frontier Group and the Hong Kong Investment Corporation Limited, the event convened more than 1,000 healthcare experts, researchers and industry leaders under the theme “EXPONENTIAL: From Breakthrough Discoveries to Global Impact.” WONDERLAB participated in the summit's scientific discussions, presented its latest research and signed the partnership agreement with UFH.

Microbiome Research in the Post-GLP-1 Era

Glucagon-like peptide-1 (GLP-1) receptor agonists are playing an increasingly important role across metabolic care, from type 2 diabetes to overweight, obesity and metabolic syndrome. As their clinical use expands, attention is extending beyond weight loss to gastrointestinal experience, individual response, body composition and long-term weight maintenance. These questions formed the basis of a summit discussion titled “Post-GLP-1 Era: Microbiome Intervention and Metabolic Health,” held as part of the “Precision Health & Human 2.0: Redefining Healthy Aging” forum. The discussion examined how microbiome research can begin with clinical questions and move toward clinical translation.

Silu Zhang, chief R&D officer of the WONDERLAB Institute of Microecology and Nutrition, joined Tao Wang, CEO of NF Nova Clinical CRO, for the discussion. Wang drew on his experience in clinical research to note that GLP-1 care increasingly requires full-cycle management, including the treatment experience, long-term tolerability and health maintenance after discontinuation—considerations that he said create a clear potential role for microbiome intervention.

Zhang emphasized that microbiome-based support should not be positioned as a substitute for GLP-1 medicines, nor should probiotics be presumed to relieve drug-related symptoms. Instead, she said, their role as an adjunctive management approach must be evaluated through rigorous research.

Zhang also said WONDERLAB has completed a two-year randomized controlled trial of SHAPE100™ Probiotics used alongside semaglutide. According to results reported by WONDERLAB, the combination group experienced significantly fewer gastrointestinal side effects during dose escalation than the semaglutide-only group and showed less weight regain during the three months after discontinuation.

Building on those findings, WONDERLAB and UFH plan to conduct a larger real-world study. The proposed work will examine the relationship between baseline gut conditions and treatment tolerability; how dietary and lifestyle changes affect the gut microbiome and weight maintenance; and the potential clinical value of microbiome intervention in improving digestive experience and treatment persistence.

A Long-Term Clinical Translation Partnership

At the summit, WONDERLAB CEO Guoxun Xiao and Carl Wu, co-founder and CEO of New Frontier Group, attended the signing ceremony. Under the agreement, WONDERLAB will contribute its work in microbiome mechanism research, strain screening and product development, while UFH will contribute clinical settings, physician networks and research execution capabilities.

The organizations will prioritize metabolic health, weight management and age-related gut health, with the goal of building a pathway from clinical questions to scientific validation, population evidence and practical solutions. They also plan to organize health lectures and educational programs to make microbiome health knowledge more accessible to the public and strengthen health-management awareness.

“This agreement marks our move from individual projects into a new phase of long-term collaboration focused on clinical translation,” Zhang said. “Our goal is to make microbiome research truly serve clinical practice and patients, and to translate scientific discoveries into tangible health value.”

From Research to Metabolic-Health Products

At its summit exhibition, WONDERLAB presented its Targeted Microbiota Weight Management Method™, a systematic approach that the company says goes beyond conventional calorie-restriction models. It also showcased a full portfolio of nutritional supplements spanning intake management, metabolic support, emotional regulation and targeted metabolic intervention. The portfolio included the morning-and-evening pairing of BODY100 PLUS™ Probiotics and SHAPE100 PLUS™ Probiotics, positioned as a time-specific, dual-track approach to gut microbiome management, as well as EASY100 PRO™ Probiotics, developed around the gut-brain axis to provide coordinated physical and emotional support for emotion-related health-management needs.

WONDERLAB also showcased AKKKING™ Multi-Effect Metabolic Probiotic Capsules, marking the product's first public appearance at an international medical summit and drawing interest from attending experts, researchers and industry representatives. According to WONDERLAB, the formula is built around 30 billion inactivated Akkermansia muciniphila cells to directly supplement this bacterium in the gut and address metabolic-health management through multiple pathways.

According to WONDERLAB, the formula is designed to activate three core pathways: GLP-1 signaling to regulate appetite, UCP-1 signaling to promote the browning of white adipose tissue, and AMPK signaling to regulate glucose and lipid metabolism. The company describes this three-pathway design as working across intake control, fat burning and metabolic regulation. WONDERLAB further reports that the formula significantly improves insulin sensitivity and helps regulate blood glucose and lipid levels.

The formulation also includes AKK BOOST™, which WONDERLAB says supports the growth of naturally occurring A. muciniphila in the gut. The company says fucoxanthin helps target visceral-fat reduction, while concentrated emblica powder helps limit carbohydrate absorption. WONDERLAB describes these ingredients as working across multiple targets to form a coordinated metabolic-health intervention. The company presented the formula as part of a broader product system spanning intake management, metabolic support, emotional well-being and targeted metabolic intervention.

From scientific discussion to partnership signing and product presentation, WONDERLAB's participation at GHS 2026 reflected its effort to connect microbiome research with clinical collaboration and consumer-health applications. The company said it will continue working with clinical partners, including UFH, to move research from mechanisms to human evidence and from laboratory findings toward clinical and everyday-health applications, with the goal of providing more precise and effective health-management solutions for consumers worldwide.

About WONDERLAB

Founded in Shenzhen in 2019, WONDERLAB is a Chinese R&D-driven biotech company in the microbiome field. It has invested over RMB 100 million in research and built a full-chain R&D system spanning strain screening, mechanism research, and clinical evaluation, anchored by its proprietary GOLDGUT® strain portfolio. WONDERLAB has established joint laboratories with institutions including the State Key Laboratory at Shandong University, Hainan University, and the China National Research Institute of Food and Fermentation Industries, and carries out clinical studies with leading Chinese hospitals such as Peking Union Medical College Hospital, Peking University Third Hospital, and the First Affiliated Hospital of Sun Yat-sen University, forming an evidence-based approach to product development. In May 2026, WONDERLAB and the Chinese Institute of Food Science and Technology (CIFST) jointly established the WONDERLAB Youth Research Fund for Microbiome and Nutritional Health, with RMB 1.5 million allocated for 2026 to support early-career researchers working on precision probiotic screening and intervention mechanisms, AI-assisted probiotic and prebiotic prediction models, and postbiotic process development and applications. WONDERLAB has been recognized by Frost & Sullivan as the No.1 probiotics brand by sales value in the Chinese mainland for three consecutive years, from January 2021 through December 2023, and its probiotic product line has recorded more than 1 billion bottles sold across all channels as of June 2026. For more information, visit www.wonderlab.top/en.

Disclaimer

Disclaimer: Probiotics and nutritional supplements are food products and are not intended to diagnose, treat, cure, or prevent any disease. The mechanisms described reflect scientific research and do not constitute product efficacy claims. This clinical study evaluates probiotic intervention for research purposes and does not constitute a product efficacy claim.

Media Contact

Jason Lee 

WONDERLAB (Shenzhen Meili Nutrition Technology Co., Ltd.) 

City: Shenzhen, China 

Telephone: +86-755-86537276 

Email: WonderLab.PR@wonderlab.top 

Address: 22/F, Tower D, China Resources Land Tower, Kefa Road, Dachong Community, Yuehai Subdistrict, Nanshan District, Shenzhen, China 

Website: www.wonderlab.top/en